Last updated: November 9, 2026
Relacorilant, formerly identified as CORT118335, is Corcept Therapeutics’ next-generation selective glucocorticoid receptor antagonist. Its lead indication is endogenous hypercortisolism, including Cushing’s syndrome. The candidate has completed the Phase 3 GRACE study and is being developed for regulatory submission. A second Phase 3 program, ROSELLA, evaluates relacorilant in combination with chemotherapy for recurrent, platinum-resistant ovarian cancer.
Relacorilant could extend Corcept’s position in Cushing’s syndrome beyond Korlym, while opening a materially larger oncology market if ROSELLA produces confirmatory results. The principal commercial risks are regulatory timing, payer adoption, competition from surgery and other cortisol-lowering therapies, and clinical differentiation against mifepristone and osilodrostat.
What is CORT118335 and how does relacorilant work?
Relacorilant is an oral glucocorticoid receptor antagonist designed to block excess cortisol signaling without clinically meaningful antagonism of the progesterone receptor. That pharmacologic profile is intended to reduce the risk of mifepristone-associated endometrial effects and eliminate the need for pregnancy-related restrictions linked to progesterone receptor blockade.
| Attribute |
Relacorilant profile |
| Development code |
CORT118335 |
| Generic name |
Relacorilant |
| Sponsor |
Corcept Therapeutics |
| Primary mechanism |
Selective glucocorticoid receptor antagonism |
| Main lead indication |
Endogenous hypercortisolism and Cushing’s syndrome |
| Oncology indication |
Recurrent, platinum-resistant ovarian cancer |
| Route |
Oral |
| Current status |
Phase 3 clinical development; not an FDA-approved product as of the latest public development disclosures used here |
| Commercial predecessor |
Korlym, or mifepristone |
Corcept positions relacorilant as a more selective glucocorticoid receptor antagonist than mifepristone. Korlym is approved for hyperglycemia secondary to endogenous Cushing’s syndrome in adults who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have failed surgery. Relacorilant is being developed for a broader hypercortisolism population.
What is the current clinical development status of relacorilant?
GRACE Phase 3 trial in hypercortisolism
The GRACE study evaluated relacorilant in adults with endogenous hypercortisolism. The trial used a randomized withdrawal design after an open-label treatment period. The principal objective was to determine whether patients maintained control of hypercortisolism-related manifestations after randomization to relacorilant or placebo.
Corcept reported positive topline GRACE results in 2023 and stated that the findings supported a potential U.S. regulatory submission. The company has described the program as intended to support an indication broader than Korlym’s current label, subject to FDA review. The clinical value proposition includes improvement in hypertension, hyperglycemia, hypokalemia, weight-related effects and other manifestations associated with excess cortisol signaling. (Corcept Therapeutics, 2023a)
The key regulatory issue is whether the GRACE dataset supports approval across the proposed hypercortisolism population or only for narrower subgroups. The FDA will assess the magnitude and durability of clinical benefit, the handling of cortisol-related biomarkers, safety monitoring and the consistency of results across disease manifestations.
ROSELLA Phase 3 trial in ovarian cancer
ROSELLA is evaluating relacorilant with nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. The biological rationale is that glucocorticoid receptor signaling may contribute to tumor survival and chemotherapy resistance in some ovarian cancers.
The study is designed to evaluate progression-free survival and overall survival in a biomarker-defined or clinically selected population. Positive results could provide a second commercial pathway for relacorilant, but the oncology program carries substantially greater development risk than the Cushing’s syndrome program. A successful ovarian cancer label would require a clinically meaningful benefit over chemotherapy alone and a safety profile compatible with repeated treatment in heavily pretreated patients. (ClinicalTrials.gov, n.d.-a)
When could relacorilant lose exclusivity?
Relacorilant has no FDA-approved product exclusivity period because it has not yet been approved. The relevant timing will depend on the patents listed in the FDA Orange Book after approval, the scope of any new chemical entity or clinical investigation exclusivity, pediatric exclusivity and any patent-term extension.
A practical exclusivity framework is:
| Protection category |
Relacorilant status |
Commercial impact |
| FDA new chemical entity exclusivity |
Potentially available if FDA treats the product as eligible |
Blocks abbreviated new drug application approval for five years, subject to statutory exceptions |
| Orphan-drug exclusivity |
Potentially relevant if an approved indication receives orphan designation |
Could provide seven years of indication-specific protection |
| New clinical investigation exclusivity |
Potentially available for qualifying new studies |
Can delay certain generic approvals for three years |
| Composition-of-matter patents |
Expected to be the primary protection layer |
Usually the strongest barrier to generic entry |
| Formulation patents |
May protect dosage forms, release characteristics or pharmaceutical compositions |
Could delay specific generic formulations |
| Method-of-use patents |
May cover treatment of hypercortisolism or oncology use |
More vulnerable to skinny-label and invalidity challenges |
| Patent-term extension |
Potentially available for regulatory review time |
Could add up to five years, subject to a 14-year post-approval cap |
No reliable Orange Book expiration date can be assigned before FDA approval and confirmation of the listed patents. Patent-family records for Corcept’s glucocorticoid receptor antagonist programs should be reviewed by jurisdiction and claim scope rather than by patent count alone. The commercial value of the estate will depend on whether issued claims cover relacorilant specifically, approved uses and commercially practical pharmaceutical compositions.
What patents protect relacorilant?
Relacorilant is protected through Corcept’s broader portfolio of glucocorticoid receptor modulator patents and related patent families. The portfolio is expected to include claims directed to:
- Relacorilant and structurally related compounds.
- Pharmaceutical compositions containing the active ingredient.
- Treatment of cortisol-mediated disorders.
- Use in patients with hypercortisolism and Cushing’s syndrome.
- Potential use in cancer patients receiving chemotherapy.
- Manufacturing processes and intermediates.
The most valuable claims are composition-of-matter claims covering relacorilant itself. Method-of-use claims can be important after launch but are more exposed to Paragraph IV challenges, label carve-outs and invalidity arguments.
Because relacorilant remains unapproved, the FDA Orange Book does not yet provide an authoritative public list of relacorilant patents. The Orange Book status of Korlym should not be treated as the patent status of CORT118335. (U.S. Food and Drug Administration, n.d.-a)
What is the FDA regulatory status of CORT118335?
Relacorilant is not an FDA-approved drug based on the latest public development disclosures used in this analysis. Corcept has reported Phase 3 clinical progress and preparation for regulatory filing, but approval, labeling, approval exclusivity and Orange Book listing remain separate milestones.
The likely FDA review questions include:
- Whether GRACE supports the proposed indication and target population.
- Whether cardiovascular, metabolic and electrolyte safety is acceptable.
- Whether glucocorticoid receptor antagonism creates clinically important adrenal insufficiency risks.
- Whether monitoring requirements can be managed in routine endocrinology practice.
- Whether the absence of progesterone receptor antagonism produces a meaningful safety advantage over mifepristone.
- Whether the oncology dataset supports a distinct label and companion biomarker strategy.
How does relacorilant compare with Korlym and Isturisa?
| Product |
Active ingredient |
Mechanism |
Approved or marketed use |
Key competitive issue |
| Korlym |
Mifepristone |
Glucocorticoid and progesterone receptor antagonist |
Cushing’s syndrome with type 2 diabetes or glucose intolerance |
Established Corcept commercial platform, but progesterone receptor activity limits use in some patients |
| Isturisa |
Osilodrostat |
Cortisol synthesis inhibitor |
Endogenous hypercortisolism |
Directly reduces cortisol production; requires monitoring for adrenal insufficiency and mineralocorticoid-related effects |
| Signifor |
Pasireotide |
Somatostatin receptor agonist |
Cushing’s disease |
Injectable or long-acting delivery and glucose-related tolerability issues |
| Relacorilant |
Relacorilant |
Selective glucocorticoid receptor antagonist |
Investigational |
Potential broader use and more selective receptor profile |
Relacorilant is most likely to compete with Korlym in receptor-level blockade and with Isturisa in medical management of endogenous hypercortisolism. Its commercial differentiation will depend on whether physicians perceive a meaningful improvement in tolerability, monitoring burden or patient eligibility.
What generic entry risks exist for relacorilant?
Generic entry is unlikely before patent and regulatory exclusivity periods expire, but Paragraph IV litigation could begin soon after an abbreviated new drug application is filed. The main challenges would likely target:
- Obviousness of the relacorilant composition.
- Written description and enablement of broad compound claims.
- Anticipation by earlier glucocorticoid receptor antagonist patents.
- Lack of clinical novelty in method-of-use claims.
- Obviousness of formulation and dosing regimens.
- Patent-term calculations and terminal disclaimers.
A generic applicant could also seek approval for a narrower label that excludes patented oncology or hypercortisolism uses. That strategy would reduce Corcept’s ability to rely on method-of-use patents alone. Composition patents and enforceable formulation claims would therefore be more important than indication claims in controlling early entry.
What manufacturing and intellectual-property barriers protect relacorilant?
The principal manufacturing barriers are likely to involve the synthesis, purification, polymorph control and scale-up of a small-molecule receptor antagonist. These barriers are weaker than biologic manufacturing barriers because generic manufacturers can generally reproduce a chemically defined active ingredient after regulatory approval and patent expiry.
Corcept may obtain additional protection through:
- Process patents for key intermediates.
- Crystalline or polymorphic forms.
- Salt or solvate forms.
- Pharmaceutical compositions.
- Stability-enhancing excipients.
- Commercially practical tablet manufacturing processes.
Manufacturing patents can extend practical protection, but they rarely replace a strong composition-of-matter patent. The most important commercial question is whether a generic can manufacture a bioequivalent product without infringing claims covering the active compound or a required solid form.
What is the market projection for relacorilant?
Cushing’s syndrome and endogenous hypercortisolism
The U.S. market for medical treatment of endogenous hypercortisolism is specialized, physician-concentrated and reimbursement-sensitive. Patient numbers are small relative to common endocrine disorders, but treatment duration can be long and annual drug costs are high.
A reasonable commercial scenario for a U.S.-led launch is:
| Scenario |
Treated patients |
Estimated net annual price |
Estimated annual revenue |
| Conservative |
2,500 |
$80,000 |
$200 million |
| Base case |
5,000 |
$110,000 |
$550 million |
| Upside |
8,000 |
$140,000 |
$1.12 billion |
These figures are scenario estimates, not company guidance. They assume successful approval, access to patients who are not adequately managed by surgery or existing drugs, and sustained reimbursement. International sales could add 20% to 50% to the U.S. opportunity over time, depending on pricing and country coverage.
The base-case opportunity is supported by Corcept’s existing endocrinology infrastructure and physician relationships. The company reported more than $500 million in annual revenue in 2023, largely from Korlym, demonstrating an existing commercial platform for cortisol-related disease. (Corcept Therapeutics, 2024)
Ovarian cancer expansion opportunity
The ovarian cancer opportunity is larger in patient count but less certain in probability-adjusted value. A positive ROSELLA result could support use in a recurrent, heavily pretreated population. Depending on label breadth, treatment duration and reimbursement, the addressable sales opportunity could exceed the Cushing’s syndrome market.
A scenario range for the oncology indication is:
| Scenario |
Probability-adjusted commercial view |
| Negative or inconclusive ROSELLA |
Relacorilant remains primarily an endocrine product |
| Positive but narrow label |
Incremental revenue of several hundred million dollars annually |
| Positive broad label with biomarker adoption |
Potential for revenue above $1 billion annually across endocrine and oncology uses |
The oncology forecast should be discounted for clinical, regulatory and reimbursement risk. It is premature to value relacorilant as a successful ovarian cancer product before mature progression-free and overall survival data are available.
Which companies are challenging the relacorilant opportunity?
The competitive landscape includes:
- Neurocrine Biosciences, with osilodrostat commercialized as Isturisa.
- Recordati and Novartis, associated with products used in Cushing’s disease and hypercortisolism.
- Corcept itself, through Korlym.
- Surgical centers and endocrinology practices, because surgery remains a central treatment option.
- Future generic manufacturers of mifepristone, osilodrostat or other cortisol-directed therapies.
- Oncology companies developing treatments for platinum-resistant ovarian cancer.
No public Paragraph IV litigation against relacorilant can be identified before an FDA-approved product and Orange Book listing create a conventional abbreviated-approval pathway. Litigation risk will increase after approval if the product achieves meaningful sales.
How strong is the relacorilant patent estate?
The estate appears commercially defensible if Corcept holds enforceable composition claims covering relacorilant and if those claims extend into the early 2030s or beyond after patent-term adjustments. The estate is less secure if protection relies mainly on treatment methods, formulations or broad genus claims.
| Estate component |
Relative strength |
| Specific composition claims |
High, if valid and unexpired |
| Broad genus claims |
Moderate; vulnerable to written-description and obviousness attacks |
| Formulation claims |
Moderate; depends on whether the formulation is necessary for bioequivalence |
| Cushing’s syndrome method claims |
Moderate to low against skinny-label entry |
| Ovarian cancer method claims |
Potentially valuable but dependent on final label and trial results |
| Manufacturing claims |
Moderate; useful as secondary barriers |
Key Takeaways
- CORT118335 is relacorilant, Corcept’s selective glucocorticoid receptor antagonist.
- The lead development program is endogenous hypercortisolism and Cushing’s syndrome.
- The GRACE Phase 3 study produced positive topline results and supports a potential regulatory filing.
- ROSELLA is evaluating relacorilant plus nab-paclitaxel in recurrent, platinum-resistant ovarian cancer.
- Relacorilant is not yet an FDA-approved product in the public status reflected here, so it has no confirmed Orange Book listing or FDA patent expiration date.
- The base-case endocrine commercial opportunity is approximately $500 million to $600 million in annual revenue, with upside above $1 billion if adoption expands.
- The oncology program creates the largest upside but also carries the highest clinical and regulatory risk.
- Composition-of-matter protection will be more important than method-of-use patents in resisting early generic entry.
- Corcept’s Korlym commercial infrastructure reduces launch risk relative to a first-time market entrant.
FAQs About CORT118335 and Relacorilant
Is CORT118335 the same drug as relacorilant?
Yes. CORT118335 is the development code for relacorilant, Corcept Therapeutics’ selective glucocorticoid receptor antagonist.
Is relacorilant approved by the FDA?
Relacorilant was not FDA-approved in the latest public development status reflected in this analysis. Its regulatory position depends on completion of the NDA process and FDA action on the GRACE dataset.
Could relacorilant replace Korlym?
Relacorilant could supplement or partially replace Korlym in Cushing’s syndrome, particularly if its selective receptor profile produces broader eligibility or improved tolerability. Korlym’s existing approval, physician familiarity and commercial base remain competitive advantages.
Does relacorilant have biosimilar risk?
No. Relacorilant is a chemically synthesized small molecule, so the relevant future competitors would be generic drugs submitted through the ANDA pathway, not biosimilars submitted under the biologics framework.
What is the largest value driver for relacorilant?
The largest value driver is successful expansion beyond the specialist Cushing’s syndrome market into ovarian cancer. The endocrine indication can support a substantial commercial product, but a positive ROSELLA outcome could materially increase the addressable market.
References
-
ClinicalTrials.gov. (n.d.-a). A study of relacorilant in combination with nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: ROSELLA. U.S. National Library of Medicine.
-
Corcept Therapeutics Incorporated. (2023a). Corcept announces positive topline results from Phase 3 GRACE study of relacorilant. Corporate press release.
-
Corcept Therapeutics Incorporated. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (n.d.-a). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (n.d.-b). Korlym prescribing information. FDA.